VEGFD was relatively up-regulated in the treated groups compared to the control group, which validated the in-silico results as the VEGFD showed to be down-regulated in cancer cells, as agreed with (Hanrahan et al. 2003; George et al. 2001). The gene discussed is VEGFD; the disease is cancer.